Subscribe
luchschenF / Shutterstock.com
20 November 2025NewsAmericasLiz Hockley

MSD wins full sweep in world’s best-selling drug clash

A PTAB dispute over $29.5bn drug reaches a dramatic conclusion, at a critical time ahead of the drug's US patent expiration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSD scores second win in patent fight over Keytruda
22 September 2025   The pharma giant invalidates a university's patent while gaining FDA approval for a new subcutaneous version of Keytruda as it protects its $29.5-billion-a-year cancer drug ahead of a looming patent cliff.
Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.


Editor's picks

INTA votes in new 2026 president at Florida leadership meeting
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

Editor's picks

Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025
Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025
Unified Patent Court
Regeneron and CureVac: UPC ‘cannot be ignored’
4 November 2025
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025

More features

INTA votes in new 2026 president at Florida leadership meeting
Sandoz wins Fed Circ reversal of $39m hair loss patent verdict
Perkins Coie and Ashurst to merge into $2.7bn revenue firm
Sanofi unit defends booster vaccine trademark in Europe
Pillsbury bags first-chair litigator and inventor with ‘business acumen’
Masimo bags $634m win over Apple—with latest watch under scrutiny
Too busy to save time? Why IP teams can’t afford to wait on AI
AZ counsel warns: EU Bolar exemption is ‘painful’ for pharma innovators